As of May 06, 2025, Ilyda SA (ILYDA.AT) has a market cap of $34.999 million USD. According to our data, Ilyda SA is ranked No.8315 in global market value.
Year | Market Cap | %Change |
---|---|---|
May 06, 2025 | $35.00 M |
69.50%
|
Dec 30, 2024 | $20.65 M |
50.74%
|
Dec 28, 2023 | $13.70 M |
13.85%
|
Dec 29, 2022 | $12.03 M |
-12.64%
|
Dec 30, 2021 | $13.77 M |
88.44%
|
Dec 30, 2020 | $7.31 M |
74.17%
|
Dec 30, 2019 | $4.20 M |
95.37%
|
Dec 30, 2018 | $2.15 M |
-6.90%
|
Dec 28, 2017 | $2.31 M |
-46.91%
|
Dec 29, 2016 | $4.35 M |
-25.93%
|
Dec 30, 2015 | $5.87 M |
-20.16%
|
Dec 30, 2014 | $7.35 M |
84.75%
|
Dec 30, 2013 | $3.98 M |
-38.46%
|
Dec 30, 2012 | $6.46 M |
144.36%
|
Dec 29, 2011 | $2.65 M |
-24.00%
|
Dec 30, 2010 | $3.48 M |
-74.26%
|
Dec 30, 2009 | $13.52 M |
-5.03%
|
Dec 30, 2008 | $14.24 M |
-21.56%
|
Dec 30, 2007 | $18.15 M |
-5.69%
|
Dec 28, 2006 | $19.25 M |
52.05%
|
Dec 29, 2005 | $12.66 M |
52.88%
|
Dec 30, 2004 | $8.28 M |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
![]() Santander
SAN
|
$111.03 B |
0.000 M
|
![]() Spain
|
![]() Novartis
NVS
|
$224.23 B |
0.160 B
|
![]() Switzerland
|
![]() GlaxoSmithKline
GSK
|
$77.05 B |
0.003 M
|
![]() UK
|
![]() Pfizer
PFE
|
$130.73 B |
-0.001 M
|
![]() USA
|
![]() AstraZeneca
AZN
|
$222.30 B |
0.004 M
|
![]() UK
|
![]() Merck
MRK
|
$212.01 B |
-0.001 M
|
![]() USA
|
![]() Johnson & Johnson
JNJ
|
$375.13 B |
0.006 M
|
![]() USA
|
![]() First Majestic Silver
AG
|
$3.03 B |
0.000 M
|
![]() Canada
|
![]() Eli Lilly
LLY
|
$794.90 B |
-0.026 M
|
![]() USA
|
![]() AbbVie
ABBV
|
$342.32 B |
-0.001 M
|
![]() USA
|
![]() Bristol-Myers Squibb
BMY
|
$98.62 B |
0.002 M
|
![]() USA
|
![]() Amgen
AMGN
|
$152.20 B |
0.126 B
|
![]() USA
|
![]() Teva Pharmaceutical Industries
TEVA
|
$18.23 B |
0.362 B
|
![]() Israel
|
![]() Novo Nordisk
NVO
|
$290.79 B |
71.582 B
|
![]() Denmark
|
Market Cap | = | ILYDA.AT Stock Price | * | ILYDA.AT Shares Outstanding |
= | $2.58 | * | 13.57 M | |
= | $35.00 M |